These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19748082)

  • 1. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
    Barr CS; Chen SA; Schwandt ML; Lindell SG; Sun H; Suomi SJ; Heilig M
    Biol Psychiatry; 2010 Jan; 67(1):78-80. PubMed ID: 19748082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.
    Vallender EJ; Rüedi-Bettschen D; Miller GM; Platt DM
    Drug Alcohol Depend; 2010 Jun; 109(1-3):252-6. PubMed ID: 20153935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques.
    Barr CS; Schwandt M; Lindell SG; Chen SA; Goldman D; Suomi SJ; Higley JD; Heilig M
    Arch Gen Psychiatry; 2007 Mar; 64(3):369-76. PubMed ID: 17339526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
    Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
    Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
    Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
    Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
    Setiawan E; Pihl RO; Benkelfat C; Leyton M
    Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
    Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
    Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice.
    Bilbao A; Robinson JE; Heilig M; Malanga CJ; Spanagel R; Sommer WH; Thorsell A
    Biol Psychiatry; 2015 May; 77(10):850-8. PubMed ID: 25442002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The μ-opioid receptor and treatment response to naltrexone.
    Thorsell A
    Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
    Kranzler HR; Armeli S; Covault J; Tennen H
    Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
    Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
    Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
    Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
    Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms.
    Henderson-Redmond AN; Lowe TE; Tian XB; Morgan DJ
    Brain Res Bull; 2018 Apr; 138():12-19. PubMed ID: 28780411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPRM1 gene variation influences hypothalamic-pituitary-adrenal axis function in response to a variety of stressors in rhesus macaques.
    Schwandt ML; Lindell SG; Higley JD; Suomi SJ; Heilig M; Barr CS
    Psychoneuroendocrinology; 2011 Oct; 36(9):1303-11. PubMed ID: 21459516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
    Ray LA; Bujarski S; Chin PF; Miotto K
    Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
    Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.